Literature DB >> 16674767

Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada.

S E Jelinski1, W J Becker, S N Christie, R Giammarco, G F Mackie, M J Gawel, A G Eloff, J E Magnusson.   

Abstract

We set out to examine selected clinical characteristics of migraine patients referred to neurologists specializing in headache in Canada, and to document their pharmacological therapy both before and after consultation with the neurologist. Demographic, clinical and pharmacotherapy data were collected at the time of consultation for 606 patients referred to five headache clinics and who were given a migraine diagnosis by the neurologist. Data were analysed as part of the Canadian Headache Outpatient Registry and Database (CHORD) Project. The mean age of the migraine patients was 39.7 years; and 82.5% were female. The majority of patients suffered severe impact from their headaches. Prior to consultation, 48.7% were taking a triptan; after consultation, 97.2% were on a triptan. Before consultation, 30.9% were on a prophylactic drug; after consultation, 70.4% were. 20.8% of patients were medication overusers. Of these medication overusers, 42.4% were overusing an opiate, usually in combination with other analgesics; 21.6% were overusing a triptan. Medication changes made by the neurologists at consultation included a large increase in the use of both triptans and prophylactic medications. Medication overuse, particularly opiate overuse, remains a significant problem in patients with migraine in Canada.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16674767     DOI: 10.1111/j.1468-2982.2005.01077.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  4 in total

Review 1.  Prophylaxis of migraine headache.

Authors:  Tamara Pringsheim; W Jeptha Davenport; Werner J Becker
Journal:  CMAJ       Date:  2010-02-16       Impact factor: 8.262

2.  Treatment of migraine and tension-type headache in Croatia.

Authors:  Vlasta Vuković; Davor Plavec; Arijana Lovrencić Huzjan; Mislav Budisić; Vida Demarin
Journal:  J Headache Pain       Date:  2010-03-06       Impact factor: 7.277

3.  Triptans in the Italian population: a drug utilization study and a literature review.

Authors:  Alessandro Panconesi; Eleonora Pavone; Franca Vacca; Monica Vaiani; Roberto Banfi
Journal:  J Headache Pain       Date:  2008-03-04       Impact factor: 7.277

4.  Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study.

Authors:  Jonathan Gladstone; Sameer Chhibber; Jagdeep Minhas; Calum S Neish; G Sarah Power; Zhiyi Lan; Driss Rochdi; Jessica Lanthier-Martel; Natacha Bastien
Journal:  Headache       Date:  2021-11-22       Impact factor: 5.311

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.